Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
| Autor: | Zeuzem, S, Flisiak, R, Vierling, J M, Mazur, W, Mazzella, G, Thongsawat, S, Abdurakhmanov, D, Van Kính, N, Calistru, P, Heo, J, Stanciu, C, Gould, M, Makara, M, Hsu, S-J, Buggisch, P, Samuel, D, Mutimer, D, Nault, B, Merz, M, Bao, W, Griffel, L H, Brass, C, Naoumov, N V, ESSENTIAL II Study Group (with Hendrik Reynaert), Reynaert, Hendrik |
|---|---|
| Přispěvatelé: | Basic (bio-) Medical Sciences, Liver Cell Biology, Laboratory of Molecullar and Cellular Therapy, Zeuzem S., Flisiak R., Vierling J.M., Mazur W., Mazzella G., Thongsawat S., Abdurakhmanov D., Van Kinh N., Calistru P., Heo J., Stanciu C., Gould M., Makara M., Hsu S.-J., Buggisch P., Samuel D., Mutimer D., Nault B., Merz M., Bao W., Griffel L.H., Brass C., Naoumov N.V. Collaborators., Craxì Antonio, Zeuzem, S, Flisiak, R., Vierling, J.M., Mazur, W., Mazzella, G., Thongsawat, S., Abdurakhmanov, D., Van Kính, N., Calistru, P., Heo, J., Stanciu, C., Gould, M., Makara, M., Hsu, S.-J., Buggisch, P., Samuel, D., Mutimer, D., Nault, B., Merz, M., Bao, W., Griffel, L.H., Brass, C., Naoumov, N.V. |
| Rok vydání: | 2015 |
| Předmět: |
Male
Phases of clinical research Hepacivirus Gastroenterology Polyethylene Glycol Polyethylene Glycols chemistry.chemical_compound Medicine Pharmacology (medical) Chronic Alisporivir Adolescent Adult Aged Antiviral Agents Cyclosporine Double-Blind Method Drug Therapy Combination Female Genotype Hepatitis C Chronic Humans Interferon-alpha Middle Aged Recombinant Proteins Ribavirin Treatment Outcome United States Young Adult Hepatitis C Recombinant Protein Combination Human United State medicine.medical_specialty Alpha interferon Placebo Drug Therapy Internal medicine Adverse effect Antiviral Agent Hepaciviru Hepatology business.industry medicine.disease Regimen chemistry Immunology business |
| Zdroj: | Alimentary pharmacologytherapeutics. 42(7) |
| ISSN: | 1365-2036 |
| Popis: | Summary Background Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection. Methods Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily [response-guided therapy (RGT) for 24 or 48 weeks or 48 weeks fixed duration] or ALV 400 mg twice daily RGT with PR, compared to PR alone. Following a Food and Drug Administration partial clinical hold, ALV/placebo was discontinued and patients completed treatment with PR only. At that time, 87% of patients had received ≥12 weeks and 20% had received ≥24 weeks of ALV/PR triple therapy. Results A total of 1081 patients were randomised (12% cirrhosis, 55% CT/TT IL28B). Addition of ALV to PR improved virological response in a dose-dependent fashion. Overall, sustained virological response (SVR12; primary endpoint) was 69% in all ALV groups vs. 53% in PR control. Highest SVR12 (90%) was achieved in patients treated with ALV 400 mg twice daily and PR for >24 weeks. Seven cases of pancreatitis were reported, with similar frequency between ALV/PR and PR control groups (0.6% vs. 0.8% respectively). Adverse events seen more frequently with ALV/PR than with PR alone were anaemia, thrombocytopenia, hyperbilirubinaemia and hypertension. Conclusions Alisporivir, especially the 400 mg twice daily regimen, increased efficacy of PR therapy in treatment-naive patients with HCV genotype 1 infection. The mechanism of action and pangenotypic activity suggest that alisporivir could be useful in interferon-free combination regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |